Radioactive antitumor agent
AssigneeNational Institutes for Quantum Science and Technology
InventorsYukie Yoshii, Hiroki Matsumoto
Life of this patent
Estimating the term…
Abstract
This radioactive antitumor agent comprises a radioactive dithiosemicarbazone-copper complex as an active ingredient, and is characterized by being used in such a way that the radioactive dithiosemicarbazone-copper complex is administered multiple times to an organism requiring tumor treatment, at a radioactive dose that avoids dose-limiting toxicity, as determined on the basis of hematological parameters. The multiple administration preferably consists of intermittent administration at time intervals allowing the hematological parameters to return to a normal range.
Claims6
A method of treating a tumor, which comprises performing multiple administration, at a predetermined time interval, of a radioactive antitumor agent comprising a radioactive dithiosemicarbazone-copper complex as an active ingredient to a living body in need of internal radiotherapy of the tumor at a radioactive dose that (1) effectively kills tumor cells/tissues as determined on the basis of tumor growth inhibition and survival prolongation, and (2) avoids dose-limiting toxicity as determined on the basis of a hematological parameter selected from the group consisting of white blood cell count, red blood cell count and platelet count,
- wherein the radioactive dose is from 30 MBq/kg to 450 MBq/kg, and
- the radioactive dithiosemicarbazone-copper complex is represented by the following formula (1):
- wherein R1, R2, R3, and R4 are each independently selected from the group consisting of a hydrogen atom, an alkyl group, and an alkoxy group, and Cu is a radioisotope of copper selected from the group consisting of 64Cu and 67Cu, and
- wherein the tumor is a malignant brain tumor.
Dependencies are inferred from the claim text.